Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:BYSI NASDAQ:GANX NASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$6.01+117.0%$2.91$1.47▼$15.49$67.66M2.831.19 million shs99.98 million shsBYSIBeyondSpring$1.77-0.8%$1.81$0.98▼$3.44$71.99M0.2444,939 shs84,001 shsGANXGain Therapeutics$1.87+3.3%$1.80$1.41▼$2.90$65.07M0.11917,245 shs670,682 shsNXTCNextCure$11.93+37.1%$5.70$2.69▼$19.20$23.28M1.3427,955 shs436,478 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+116.97%+113.88%+163.60%+151.46%-55.81%BYSIBeyondSpring-0.84%+1.72%-1.12%-18.81%-25.94%GANXGain Therapeutics+3.31%-5.08%+18.35%+17.98%-35.96%NXTCNextCure+37.13%+79.40%+114.95%+139.08%-32.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$6.01+117.0%$2.91$1.47▼$15.49$67.66M2.831.19 million shs99.98 million shsBYSIBeyondSpring$1.77-0.8%$1.81$0.98▼$3.44$71.99M0.2444,939 shs84,001 shsGANXGain Therapeutics$1.87+3.3%$1.80$1.41▼$2.90$65.07M0.11917,245 shs670,682 shsNXTCNextCure$11.93+37.1%$5.70$2.69▼$19.20$23.28M1.3427,955 shs436,478 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+116.97%+113.88%+163.60%+151.46%-55.81%BYSIBeyondSpring-0.84%+1.72%-1.12%-18.81%-25.94%GANXGain Therapeutics+3.31%-5.08%+18.35%+17.98%-35.96%NXTCNextCure+37.13%+79.40%+114.95%+139.08%-32.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 2.60Moderate Buy$18.25203.66% UpsideBYSIBeyondSpring 1.00SellN/AN/AGANXGain Therapeutics 2.75Moderate Buy$7.86320.17% UpsideNXTCNextCure 2.25Hold$25.50113.75% UpsideCurrent Analyst Ratings BreakdownLatest NXTC, GANX, BYSI, and ARTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025ARTVArtiva BiotherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$18.00 ➝ $23.0010/17/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.0010/15/2025GANXGain TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.0010/13/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.0010/8/2025ARTVArtiva BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BYSIBeyondSpringWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025GANXGain TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NXTCNextCureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025GANXGain TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $7.009/27/2025ARTVArtiva BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BYSIBeyondSpringWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K587.30N/AN/A$7.68 per share0.78BYSIBeyondSpring$1.75M40.79N/AN/A($0.37) per share-4.78GANXGain Therapeutics$50K1,344.53N/AN/A$0.28 per share6.68NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)BYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/A11/12/2025 (Estimated)GANXGain Therapeutics-$20.41M-$0.63N/AN/AN/AN/A-289.10%-155.11%11/13/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)Latest NXTC, GANX, BYSI, and ARTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025GANXGain Therapeutics-$0.15N/AN/AN/AN/AN/A11/11/2025Q3 2025ARTVArtiva Biotherapeutics-$0.90N/AN/AN/AN/AN/A11/6/2025Q3 2025NXTCNextCure-$4.06N/AN/AN/AN/AN/A8/13/2025Q2 2025BYSIBeyondSpringN/A-$0.04N/A-$0.04N/AN/A8/12/2025Q2 2025GANXGain Therapeutics-$0.17-$0.19-$0.02-$0.19N/AN/A8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/A8/6/2025Q2 2025ARTVArtiva Biotherapeutics-$0.84-$0.87-$0.03-$0.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A13.8413.84BYSIBeyondSpringN/A2.192.19GANXGain Therapeutics0.091.791.79NXTCNextCureN/A3.713.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/ABYSIBeyondSpring40.29%GANXGain Therapeutics11.97%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%BYSIBeyondSpring29.31%GANXGain Therapeutics7.18%NXTCNextCure17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.43 million19.20 millionN/ABYSIBeyondSpring8040.33 million28.51 millionOptionableGANXGain Therapeutics2035.95 million33.37 millionOptionableNXTCNextCure902.68 million2.20 millionOptionableNXTC, GANX, BYSI, and ARTV HeadlinesRecent News About These CompaniesCompanies Like NextCure (NASDAQ:NXTC) Could Be Quite RiskyOctober 18 at 9:25 AM | finance.yahoo.comNextCure, Simcere Zaiming announce expansion of Phase 1 trial of SIM0505October 16 at 7:25 PM | msn.comNextCure, Inc. and Simcere Zaiming Announce Dosing of First U.S. Patient in Phase 1 Trial of SIM0505 for Advanced Solid TumorsOctober 16 at 8:31 AM | quiverquant.comQNextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United StatesOctober 16 at 8:05 AM | globenewswire.comNextCure (NASDAQ:NXTC) Shares Up 1.2% - What's Next?October 8, 2025 | americanbankingnews.comNextCure to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comNextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | bakersfield.comBNextCure Reports Q2 2025 Results and Strategic UpdatesAugust 7, 2025 | tipranks.comNextCure (NXTC) Q2 Loss Widens 71%August 7, 2025 | fool.comNextCure Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comNextCure presents new preclinical data on osteogenesis imperfecta treatmentJuly 25, 2025 | msn.comNextCure stock soars after positive data for bone disease treatmentJuly 25, 2025 | investing.comNextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease TreatmentJuly 25, 2025 | msn.comPreclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis ImperfectaJuly 24, 2025 | globenewswire.comNextCure, Inc. (NXTC) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comNextCure shareholders approve board elections and reverse stock split proposalJune 25, 2025 | uk.investing.comNextCure shareholders approve board elections and reverse stock split proposal - Investing.comJune 25, 2025 | investing.comNextcure stock drops near 30% on $745M ADC deal with SimcereJune 18, 2025 | bioworld.comBNextCure Joins China-ADC Gold Rush with $745M Simcere DealJune 17, 2025 | biospace.comBNextCure tanks as it teams up with Simcere on novel ADCJune 17, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXTC, GANX, BYSI, and ARTV Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$6.01 +3.24 (+116.97%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$5.49 -0.52 (-8.65%) As of 10/17/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.BeyondSpring NASDAQ:BYSI$1.77 -0.02 (-0.84%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.56%) As of 10/17/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Gain Therapeutics NASDAQ:GANX$1.87 +0.06 (+3.31%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.82 -0.05 (-2.41%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.NextCure NASDAQ:NXTC$11.93 +3.23 (+37.13%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$11.82 -0.11 (-0.88%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
